A citation-based method for searching scientific literature

Juan Jose Garcia Sanchez, Juliette Thompson, David A Scott, Rachel Evans, Naveen Rao, Elisabeth Sörstadius, Glen James, Stephen Nolan, Eric T Wittbrodt, Alyshah Abdul Sultan, Bergur V Stefansson, Dan Jackson, Keith R Abrams. Adv Ther 2022
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Brendon L Neuen, Clare Arnott, Vlado Perkovic, Gemma Figtree, Dick de Zeeuw, Greg Fulcher, Min Jun, Meg J Jardine, Sophia Zoungas, Carol Pollock,[...]. Diabetes Obes Metab 2021
22
50


Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90).
Jose Leal, Maria Alva, Vanessa Gregory, Alison Hayes, Borislava Mihaylova, Alastair M Gray, Rury R Holman, Philip Clarke. Diabet Med 2021
2
50

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial.
Min Jun, Katie Harris, Hiddo J L Heerspink, Sunil V Badve, Meg J Jardine, Stephen Harrap, Pavel Hamet, Michel Marre, Neil Poulter, Sradha Kotwal,[...]. Diabetes Obes Metab 2021
2
50

A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences.
Thomas J Hoerger, John S Wittenborn, Joel E Segel, Nilka R Burrows, Kumiko Imai, Paul Eggers, Meda E Pavkov, Regina Jordan, Susan M Hailpern, Anton C Schoolwerth,[...]. Am J Kidney Dis 2010
65
50

Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016.
Yiling J Cheng, Alka M Kanaya, Maria Rosario G Araneta, Sharon H Saydah, Henry S Kahn, Edward W Gregg, Wilfred Y Fujimoto, Giuseppina Imperatore. JAMA 2019
170
50



Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Amanda I Adler, Richard J Stevens, Sue E Manley, Rudy W Bilous, Carole A Cull, Rury R Holman. Kidney Int 2003
50

Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Catherine M Clase, Joshua Barzilay, Peggy Gao, Andrew Smyth, Roland E Schmieder, Sheldon Tobe, Koon K Teo, Salim Yusuf, Johannes F E Mann. Kidney Int 2017
46
50

Calibrating models in economic evaluation: a seven-step approach.
Tazio Vanni, Jonathan Karnon, Jason Madan, Richard G White, W John Edmunds, Anna M Foss, Rosa Legood. Pharmacoeconomics 2011
91
50


SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
321
50

The changing natural history of nephropathy in type I diabetes.
A S Krolewski, J H Warram, A R Christlieb, E J Busick, C R Kahn. Am J Med 1985
773
50

Trajectories of kidney function in diabetes: a clinicopathological update.
Megumi Oshima, Miho Shimizu, Masayuki Yamanouchi, Tadashi Toyama, Akinori Hara, Kengo Furuichi, Takashi Wada. Nat Rev Nephrol 2021
12
50


Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO).
Hui Shao, Vivian Fonseca, Charles Stoecker, Shuqian Liu, Lizheng Shi. Pharmacoeconomics 2018
36
50

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
332
50

Intensive BP Control and eGFR Declines: Are These Events Due to Hemodynamic Effects and Are Changes Reversible?
Debbie C Chen, Wendy McCallum, Mark J Sarnak, Elaine Ku. Curr Cardiol Rep 2020
2
50

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
50


New pharmacological strategies for protecting kidney function in type 2 diabetes.
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. Lancet Diabetes Endocrinol 2019
43
50


Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.
Srinivasan Beddhu, Jincheng Shen, Alfred K Cheung, Paul L Kimmel, Glenn M Chertow, Guo Wei, Robert E Boucher, Michel Chonchol, Farid Arman, Ruth C Campbell,[...]. J Am Soc Nephrol 2019
26
50

Cost-of-illness study of type 2 diabetes mellitus in Colombia.
Juan Camilo González, John H Walker, Thomas R Einarson. Rev Panam Salud Publica 2009
20
50

Direct medical costs of end-stage kidney disease and renal replacement therapy: a cohort study in Guangzhou City, southern China.
Hui Zhang, Chao Zhang, Sufen Zhu, Hongjian Ye, Donglan Zhang. BMC Health Serv Res 2020
4
50

An economic model of the long-term health care burden of Type II diabetes.
A Bagust, P K Hopkinson, W Maier, C J Currie. Diabetologia 2001
72
50

Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial.
Nobuya Inagaki, Wenying Yang, Hirotaka Watada, Linong Ji, Sven Schnaidt, Egon Pfarr, Tomoo Okamura, Odd Erik Johansen, Jyothis T George, Maximilian von Eynatten,[...]. Diabetol Int 2019
15
50

Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan.
Kunitoshi Iseki, Yoshiharu Ikemiya, Kozen Kinjo, Chiho Iseki, Shuichi Takishita. Clin Exp Nephrol 2004
18
50

Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?
Ylenia Ingrasciotta, Janet Sultana, Dario Formica, Valentina Ientile, Andrea Aiello, Alessandro Chinellato, Daniele Ugo Tari, Rosa Gini, Maurizio Pastorello, Salvatore Scondotto,[...]. Pharmacoepidemiol Drug Saf 2021
3
50

A computer simulation model of diabetes progression, quality of life, and cost.
Honghong Zhou, Deanna J M Isaman, Shari Messinger, Morton B Brown, Ronald Klein, Michael Brandle, William H Herman. Diabetes Care 2005
79
50

Economic Simulation Modeling in Type 2 Diabetes.
Rahul S Dadwani, Neda Laiteerapong. Curr Diab Rep 2020
4
50

Chronic kidney disease.
Kamyar Kalantar-Zadeh, Tazeen H Jafar, Dorothea Nitsch, Brendon L Neuen, Vlado Perkovic. Lancet 2021
87
50

Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus.
Pooyan Kazemian, Deborah J Wexler, Naomi F Fields, Robert A Parker, Amy Zheng, Rochelle P Walensky. Diabetes Technol Ther 2019
4
50

Pharmacoeconomic analysis of angiotensin-converting enzyme inhibitors in type 2 diabetes: a Markov model.
Heather M Campbell, Kathy D Boardman, Melanie A Dodd, Dennis W Raisch. Ann Pharmacother 2007
7
50

Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).
Michael Willis, Pierre Johansen, Andreas Nilsson, Christian Asseburg. Pharmacoeconomics 2017
20
50


Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial.
Hirotaka Watada, Hiroyuki Sakamaki, Daisuke Yabe, Fumiko Yamamoto, Tatsunori Murata, Keigo Hanada, Tetsuaki Hirase, Tomoo Okamura. Diabetes Ther 2020
2
50

Ethnic differences in mortality and hospital admission rates between Māori, Pacific, and European New Zealanders with type 2 diabetes between 1994 and 2018: a retrospective, population-based, longitudinal cohort study.
Dahai Yu, Zhanzheng Zhao, Uchechukwu Levi Osuagwu, Karen Pickering, John Baker, Richard Cutfield, Brandon J Orr-Walker, Yamei Cai, David Simmons. Lancet Glob Health 2021
12
50

Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster.
Ping Tyug Loh, Matthias Paul Han Sim Toh, Joseph Antonio Molina, Anantharaman Vathsala. Nephrology (Carlton) 2015
13
50

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Andrew J Palmer, Stéphane Roze, William J Valentine, Michael E Minshall, Volker Foos, Francesco M Lurati, Morten Lammert, Giatgen A Spinas. Curr Med Res Opin 2004
362
50

Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model.
Elvira Mueller, Stefanie Maxion-Bergemann, Dmitry Gultyaev, Stefan Walzer, Nick Freemantle, Chantal Mathieu, Bjorn Bolinder, Robert Gerber, Marion Kvasz, Rito Bergemann. Diabetes Technol Ther 2006
30
50


Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
J J Caro, W S Klittich, G Raggio, P L Kavanagh, J A O'Brien, L A Shomphe, K M Flegel, C Copley-Merriman, C Sigler. Clin Ther 2000
17
50

Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota.
L L Humphrey, D J Ballard, P P Frohnert, C P Chu, W M O'Fallon, P J Palumbo. Ann Intern Med 1989
190
50

Developing a health economic model for Asians with type 2 diabetes based on the Japan Diabetes Complications Study and the Japanese Elderly Diabetes Intervention Trial.
Shiro Tanaka, Jakob Langer, Tim Morton, Nicki Hoskins, Lars Wilkinson, Sachiko Tanaka-Mizuno, Ryo Kawasaki, Tatsumi Moriya, Chika Horikawa, Rei Aida,[...]. BMJ Open Diabetes Res Care 2021
2
50

Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines.
N van Os, L W Niessen, H J Bilo, A F Casparie, B A van Hout. Health Policy 2000
22
50

Cost-Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand.
Chaicharn Deerochanawong, Kriengsak Vareesangthip, Dilok Piyayotai, Dittaya Thongsuk, Nuch Pojchaijongdee, Unchalee Permsuwan. Diabetes Ther 2021
2
50

Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019.
Yujiao Deng, Na Li, Ying Wu, Meng Wang, Si Yang, Yi Zheng, Xinyue Deng, Dong Xiang, Yuyao Zhu, Peng Xu,[...]. Front Endocrinol (Lausanne) 2021
12
50

Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry.
Katherine R Tuttle, Radica Z Alicic, O Kenrik Duru, Cami R Jones, Kenn B Daratha, Susanne B Nicholas, Sterling M McPherson, Joshua J Neumiller, Douglas S Bell, Carol M Mangione,[...]. JAMA Netw Open 2019
57
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.